Vironil-A 25 mg (Tablet)
Unit Price: ৳ 90.00 (1 x 10: ৳ 900.00)
Strip Price: ৳ 900.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Tenofovir alafenamide |
| Company | Unimed unihealth pharmaceuticals ltd |
Indications
- Treatment of chronic hepatitis B virus infection in adults with compensated liver disease
Pharmacology
- Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor
- Tenofovir alafenamide is converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes
- Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase
Dosage & Administration
- Recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food
- No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute
- Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment
Interaction
- Vironil-A is a substrate of P-glycoprotein (P-gp) and BCRP
- Coadministration of Vironil-A with other drugs that inhibit P-gp and BCRP may increase the absorption & plasma concentration of Vironil-A
- Coadministration of Vironil-A with drugs that strongly affect P-gp and BCRP activity may lead to changes in Vironil-A absorption
Side Effects
- Headache
- Stomach pain
- Tiredness
- Cough
- Nausea
- Back pain
Pregnancy & Lactation
- Prevalence of birth defects in live births following first trimester exposure to TAF-containing regimens was 4.2%
- It is not known whether Tenofovir alafenamide & its metabolites are present in human breast milk
Precautions & Warnings
- Discontinuation of anti-hepatitis B therapy, including Vironil-A may result in severe acute exacerbations of hepatitis B
- Due to the risk of development of HIV-1 resistance Vironil-A alone is not recommended for the treatment of HIV-1 infection
- Postmarketing cases of renal impairment, including acute renal failure, have been reported with TAF-containing products
Overdose Effects
- If overdose occurs, monitor patient for evidence of toxicity
- Treatment of overdosage with Vironil-A consists of general supportive measures including monitoring of vital signs
Therapeutic Class
- Hepatic viral infections (Hepatitis B)
Storage Conditions
- Store below 30°C
- Keep it in its original container
- Protect from light
- Keep out of children’s reach